Avidity Historical Balance Sheet

RNA Stock

USD 43.33 0.47 1.07%

Trend analysis of Avidity Biosciences balance sheet accounts such as Other Liabilities of 1.1 M, Accounts Payable of 4.5 M, Cash of 189.2 M or Other Assets of 0.95 provides information on Avidity Biosciences' total assets, liabilities, and equity, which is the actual value of Avidity Biosciences to its prevalent stockholders. By breaking down trends over time using Avidity Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Avidity Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Avidity Biosciences is a good buy for the upcoming year.

Avidity Biosciences Inventory

(6.97 Million)

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Avidity Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.

About Avidity Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Avidity Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Avidity Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Avidity Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Avidity currently owns. An asset can also be divided into two categories, current and non-current.

Avidity Biosciences Balance Sheet Chart

At present, Avidity Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 84.7 M, whereas Other Current Liabilities is forecasted to decline to about 20.9 M.

Total Assets Other Current Liab Other Liab Non Currrent Assets Other

Add Fundamental

Total Assets

Total assets refers to the total amount of Avidity Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Avidity Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Most accounts from Avidity Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Avidity Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Avidity Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.At present, Avidity Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 84.7 M, whereas Other Current Liabilities is forecasted to decline to about 20.9 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	28.0M	60.9M	36.2M	20.9M
Total Assets	427.6M	638.8M	628.6M	660.0M

Other Current Liab Total Assets

Avidity Biosciences balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Long Term Debt	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total
Total Assets		0.84	0.92	0.99	-0.19	0.72	0.8	0.07	-0.69	1.0	0.33	-0.64	-0.8	0.93	-0.16	0.99	0.89	-0.81	-0.91	0.9	0.85	0.96	-0.85	0.86	-0.86	-0.28
Other Current Liab	0.84		0.73	0.87	-0.11	0.58	0.73	0.41	-0.58	0.87	0.17	-0.23	-0.64	0.83	0.13	0.8	0.87	-0.71	-0.72	0.87	0.65	0.88	-0.63	0.77	-0.63	-0.39
Total Current Liabilities	0.92	0.73		0.88	-0.24	0.67	0.52	-0.06	-0.61	0.9	0.4	-0.64	-0.67	0.93	0.03	0.93	0.8	-0.53	-0.99	0.8	0.68	0.82	-0.68	0.87	-0.69	-0.17
Total Stockholder Equity	0.99	0.87	0.88		-0.19	0.73	0.84	0.11	-0.66	0.99	0.19	-0.57	-0.76	0.92	-0.13	0.98	0.89	-0.83	-0.88	0.89	0.79	0.96	-0.8	0.8	-0.81	-0.42
Other Liab	-0.19	-0.11	-0.24	-0.19		0.1	0.09	0.64	-0.02	-0.24	0.02	0.53	-0.09	-0.24	-0.38	-0.31	-0.31	0.04	0.38	-0.3	0.0	-0.23	-0.01	-0.25	0.0	0.32
Accounts Payable	0.72	0.58	0.67	0.73	0.1		0.59	0.01	-0.63	0.68	0.25	-0.34	-0.68	0.56	-0.46	0.73	0.55	-0.59	-0.65	0.56	0.63	0.75	-0.66	0.64	-0.66	-0.23
Cash	0.8	0.73	0.52	0.84	0.09	0.59		0.37	-0.65	0.81	0.11	-0.34	-0.78	0.69	-0.38	0.75	0.75	-0.98	-0.51	0.77	0.83	0.84	-0.84	0.57	-0.83	-0.35
Other Assets	0.07	0.41	-0.06	0.11	0.64	0.01	0.37		-0.32	0.09	-0.09	0.64	-0.31	0.15	0.01	-0.04	0.16	-0.29	0.17	0.17	0.19	0.12	-0.16	0.01	-0.14	0.0
Long Term Debt	-0.69	-0.58	-0.61	-0.66	-0.02	-0.63	-0.65	-0.32		-0.69	-0.42	0.23	0.96	-0.64	0.44	-0.69	-0.61	0.73	0.57	-0.63	-0.83	-0.73	0.84	-0.65	0.84	-0.07
Other Current Assets	1.0	0.87	0.9	0.99	-0.24	0.68	0.81	0.09	-0.69		0.32	-0.63	-0.79	0.93	-0.11	0.98	0.91	-0.82	-0.9	0.92	0.84	0.97	-0.84	0.86	-0.85	-0.3
Total Liab	0.33	0.17	0.4	0.19	0.02	0.25	0.11	-0.09	-0.42	0.32		-0.47	-0.5	0.27	-0.24	0.29	0.33	-0.16	-0.41	0.34	0.6	0.36	-0.56	0.66	-0.57	0.76
Intangible Assets	-0.64	-0.23	-0.64	-0.57	0.53	-0.34	-0.34	0.64	0.23	-0.63	-0.47		0.36	-0.53	0.16	-0.67	-0.51	0.38	0.72	-0.52	-0.55	-0.56	0.57	-0.61	0.58	-0.01
Common Stock	-0.8	-0.64	-0.67	-0.76	-0.09	-0.68	-0.78	-0.31	0.96	-0.79	-0.5	0.36		-0.7	0.51	-0.77	-0.69	0.84	0.63	-0.71	-0.95	-0.83	0.95	-0.73	0.95	-0.08
Property Plant Equipment	0.93	0.83	0.93	0.92	-0.24	0.56	0.69	0.15	-0.64	0.93	0.27	-0.53	-0.7		0.14	0.92	0.93	-0.69	-0.91	0.93	0.72	0.87	-0.7	0.85	-0.71	-0.31
Short Long Term Debt Total	-0.16	0.13	0.03	-0.13	-0.38	-0.46	-0.38	0.01	0.44	-0.11	-0.24	0.16	0.51	0.14		-0.14	0.14	0.42	-0.07	0.1	-0.48	-0.19	0.53	0.0	0.53	-0.25
Net Tangible Assets	0.99	0.8	0.93	0.98	-0.31	0.73	0.75	-0.04	-0.69	0.98	0.29	-0.67	-0.77	0.92	-0.14		0.88	-0.78	-0.94	0.89	0.8	0.95	-0.81	0.85	-0.82	-0.34
Property Plant And Equipment Net	0.89	0.87	0.8	0.89	-0.31	0.55	0.75	0.16	-0.61	0.91	0.33	-0.51	-0.69	0.93	0.14	0.88		-0.76	-0.83	1.0	0.76	0.92	-0.73	0.9	-0.73	-0.31
Net Debt	-0.81	-0.71	-0.53	-0.83	0.04	-0.59	-0.98	-0.29	0.73	-0.82	-0.16	0.38	0.84	-0.69	0.42	-0.78	-0.76		0.53	-0.78	-0.87	-0.87	0.88	-0.6	0.88	0.32
Retained Earnings	-0.91	-0.72	-0.99	-0.88	0.38	-0.65	-0.51	0.17	0.57	-0.9	-0.41	0.72	0.63	-0.91	-0.07	-0.94	-0.83	0.53		-0.83	-0.67	-0.84	0.67	-0.89	0.68	0.21
Non Current Assets Total	0.9	0.87	0.8	0.89	-0.3	0.56	0.77	0.17	-0.63	0.92	0.34	-0.52	-0.71	0.93	0.1	0.89	1.0	-0.78	-0.83		0.78	0.93	-0.75	0.9	-0.75	-0.3
Non Currrent Assets Other	0.85	0.65	0.68	0.79	0.0	0.63	0.83	0.19	-0.83	0.84	0.6	-0.55	-0.95	0.72	-0.48	0.8	0.76	-0.87	-0.67	0.78		0.88	-1.0	0.81	-0.99	0.11
Cash And Short Term Investments	0.96	0.88	0.82	0.96	-0.23	0.75	0.84	0.12	-0.73	0.97	0.36	-0.56	-0.83	0.87	-0.19	0.95	0.92	-0.87	-0.84	0.93	0.88		-0.87	0.88	-0.87	-0.28
Common Stock Total Equity	-0.85	-0.63	-0.68	-0.8	-0.01	-0.66	-0.84	-0.16	0.84	-0.84	-0.56	0.57	0.95	-0.7	0.53	-0.81	-0.73	0.88	0.67	-0.75	-1.0	-0.87		-0.77	1.0	-0.08
Common Stock Shares Outstanding	0.86	0.77	0.87	0.8	-0.25	0.64	0.57	0.01	-0.65	0.86	0.66	-0.61	-0.73	0.85	0.0	0.85	0.9	-0.6	-0.89	0.9	0.81	0.88	-0.77		-0.78	0.04
Long Term Debt Total	-0.86	-0.63	-0.69	-0.81	0.0	-0.66	-0.83	-0.14	0.84	-0.85	-0.57	0.58	0.95	-0.71	0.53	-0.82	-0.73	0.88	0.68	-0.75	-0.99	-0.87	1.0	-0.78		-0.08
Non Current Liabilities Total	-0.28	-0.39	-0.17	-0.42	0.32	-0.23	-0.35	0.0	-0.07	-0.3	0.76	-0.01	-0.08	-0.31	-0.25	-0.34	-0.31	0.32	0.21	-0.3	0.11	-0.28	-0.08	0.04	-0.08

Click cells to compare fundamentals

Avidity Biosciences Account Relationship Matchups

Avidity Biosciences balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	96.9M	333.9M	427.6M	638.8M	628.6M	660.0M
Other Current Liab	1.3M	10.9M	28.0M	60.9M	36.2M	20.9M
Total Current Liabilities	10.2M	14.6M	29.7M	51.9M	80.7M	84.7M
Total Stockholder Equity	(65.4M)	306.2M	381.4M	578.1M	500.8M	525.8M
Other Liab	15.1M	12.2M	6.5M	1.2M	1.1M	1.1M
Accounts Payable	2.3M	7.7M	2.8M	4.6M	8.8M	4.5M
Cash	94.6M	328.1M	405.5M	340.4M	185.1M	189.2M
Other Assets	600K	298K	850K	849K	1.0	0.95
Other Current Assets	1.1M	3.5M	5.6M	8.3M	7.3M	7.7M
Total Liab	162.3M	27.7M	46.2M	60.7M	127.8M	70.7M
Common Stock	1K	4K	5K	7K	8K	7.6K
Property Plant Equipment	631K	1.9M	15.6M	15.0M	17.3M	18.1M
Short Long Term Debt Total	4.9M	938K	10.0M	10.7M	9.9M	8.6M
Net Tangible Assets	(65.4M)	306.2M	381.4M	578.1M	664.8M	698.0M
Property Plant And Equipment Net	631K	1.5M	15.6M	15.0M	16.7M	9.2M
Net Debt	(89.6M)	(327.2M)	(395.6M)	(329.7M)	(175.2M)	(184.0M)
Retained Earnings	(22.2M)	(66.5M)	(184.5M)	(358.5M)	(570.8M)	(542.2M)
Non Current Assets Total	1.2M	2.2M	16.4M	15.9M	17.2M	9.9M
Non Currrent Assets Other	600K	501K	599K	598K	596K	537.5K
Cash And Short Term Investments	94.6M	328.1M	405.5M	610.7M	595.4M	373.5M
Common Stock Shares Outstanding	37.5M	21.7M	41.4M	52.2M	73.0M	45.2M
Liabilities And Stockholders Equity	96.9M	333.9M	427.6M	638.8M	628.6M	390.4M
Non Current Liabilities Total	152.0M	13.1M	16.5M	8.8M	47.1M	37.1M
Capital Lease Obligations	393K	938K	11.7M	7.6M	9.9M	5.6M
Other Stockholder Equity	(43.2M)	38.9M	566.2M	939.3M	1.1B	1.1B
Net Invested Capital	(60.8M)	306.2M	381.4M	578.1M	500.8M	307.1M
Property Plant And Equipment Gross	631K	1.5M	15.6M	15.0M	21.9M	23.0M
Total Current Assets	95.7M	331.7M	411.1M	622.9M	611.3M	380.6M
Accumulated Other Comprehensive Income	(134.7M)	(5K)	(187K)	(2.7M)	125K	131.3K
Capital Stock	0.0	4K	5K	7K	8K	7.6K
Net Working Capital	85.4M	317.1M	381.5M	571.0M	530.6M	345.5M
Short Term Debt	2.8M	7.7M	3.5M	6.2M	7.3M	5.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

When determining whether Avidity Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avidity Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avidity Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avidity Biosciences Stock:

How To Invest In Avidity

Details

Is Avidity Stock a good investment?

Details

What is Avidity Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.

You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. If investors know Avidity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avidity Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.88)

Revenue Per Share

0.103

Quarterly Revenue Growth

(0.17)

Return On Assets

(0.18)

Return On Equity

(0.28)

The market value of Avidity Biosciences is measured differently than its book value, which is the value of Avidity that is recorded on the company's balance sheet. Investors also form their own opinion of Avidity Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Avidity Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avidity Biosciences' market value can be influenced by many factors that don't directly affect Avidity Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Avidity Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avidity Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avidity Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Avidity Historical Balance Sheet

Avidity Biosciences Inventory

(6.97 Million)

About Avidity Balance Sheet Analysis

Avidity Biosciences Balance Sheet Chart

Total Assets

Non Currrent Assets Other

Avidity Biosciences balance sheet Correlations

Avidity Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Avidity Biosciences balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Long Term Debt Total	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Assets
Other Current Assets	+ 0.99	Total Stockholder Equity

Common Stock Total Equity	- 1.0	Non Currrent Assets Other
Long Term Debt Total	- 0.99	Non Currrent Assets Other
Retained Earnings	- 0.99	Total Current Liabilities
Net Debt	- 0.98	Cash
Non Currrent Assets Other	- 0.95	Common Stock
Retained Earnings	- 0.94	Net Tangible Assets